IDose TR (travoprost) is an implant that's placed into your eye by your ophthalmologist (eye doctor). It works to deliver a steady amount of medication to lower pressure in the eye in adults with open-angle glaucoma or ocular hypertension (high pressure in the eye). Unlike travoprost eye drops, you only need to get iDose TR (travoprost) placed once and it can last up to 3 years. IDose TR (travoprost) can cause some eye discomfort as a side effect, as well as dry or red eyes, but these effects are typically mild and go away with time.
To lower eye pressure (intraocular pressure, IOP) for:
Fluid build-up in the eye (ocular hypertension)
IDose TR (travoprost) is a prostaglandin eye implant. It helps fluid drain from inside the eye which helps lower pressure inside the eye.
Source: DailyMed
Side effects that you should report to your care team as soon as possible:
Side effects that usually do not require medical attention (report these to your care team if they continue or are bothersome):
Implant lasts up to 3 years, sometimes longer
Most side effects are mild and temporary
Can help reduce the need to use glaucoma eye drops
There's no generic version available
Can permanently change the color of your eye
Can affect MRI scans you might need in the future
It's possible that your eye color might appear more brown after getting iDose TR (travoprost) placed, and this could be permanent. This discoloration may not be noticeable for several months to years.
Follow your eye specialist's instructions for after your iDose TR (travoprost) procedure. Most people recover within a day or two and can resume normal daily activities.
It's not easy to tell if your eye pressure is improving at home. Your ophthalmologist will check how well iDose TR (travoprost) is working for you through regular eye exams. Ask your ophthalmologist or care team how often you need to come into the office for an eye exam.
Contact your ophthalmologist immediately if your eye becomes red, sensitive to light, painful, or if you develop a change in your vision. These could be signs of an issue with your implant and you need to be seen right away.
If your healthcare professional says you need a magnetic resonance imaging (MRI) scan, make sure to tell them that you have iDose TR (travoprost) in your eye. The MRI operator will need to adjust the MRI settings in order to avoid injury to you.
IDose TR (travoprost) can cause some serious health issues. This risk may be even higher for certain groups. If this worries you, talk to your doctor or pharmacist about other options.
IDose TR (travoprost) is supposed to be anchored within your eye, but it's possible that the implant can dislocate and travel where it's not supposed to be. Your ophthalmologist will check the implant's location regularly with an eye exam, so make sure to keep your appointments with them. If the implant does happen to move, they'll need to remove it surgically.
Risk factors: Eye inflammation | Eye infection
People who received travoprost eye drops and iDose TR (travoprost) have reported inflammation of the eyes (macular edema). Let your eye specialist know if you have had cataract surgery because this can raise your risk of macular edema; they might need to monitor your eye more closely after you receive iDose TR (travoprost).
In addition, let your ophthalmologist know if you already have red, itchy, or painful eyes from other conditions, such as an eye infection, before getting iDose TR (travoprost) placed. Receiving iDose TR (travoprost) can worsen redness or swelling of the eye.
Notify your ophthalmologist if you notice any blurry vision or vision changes once iDose TR (travoprost) is placed.
Risk factors: Injury or damage to the surface of the eye
Eye procedures, such as receiving a iDose TR (travoprost) implant, can cause a bacterial infection within the eye. To minimize this risk, your ophthalmologist will implant iDose TR (travoprost) in a clean and sterile environment; take care to avoid touching your eyes if your hands are dirty, especially right after the procedure. Contact your ophthalmologist if you notice redness, discharge, or pain in your eye.
Using travoprost can lead to darkening of eye color over time. This might not be noticeable for several months or years after starting treatment. Darkening of eye color isn't harmful, but can become permanent even after you stop using travoprost. Your eye specialist will check your eyes regularly during treatment to make sure they're healthy.
If another healthcare professional says you need a magnetic resonance imaging (MRI) scan, tell them that you have iDose TR (travoprost) implanted in your eye. The MRI technician will need to adjust the machine settings so that it won't cause injury to you.
Each iDose TR (travoprost) contains 75 mcg of travoprost.
Your ophthalmologist will place 1 implant into the affected eye(s) once. The implant will continuously release travoprost into the eye. Your ophthalmologist will let you know if you need to replace the implant later on.
Active eye infection
Corneal endothelial cell dystrophy (e.g., Fuch's Dystrophy)
Past cornea transplant or endothelial cell transplant (e.g., DSAEK)
To lower eye pressure (intraocular pressure, IOP) for:
Fluid build-up in the eye (ocular hypertension)
Open-angle glaucoma
High pressure in the eye (ocular hypertension)
Fluid build-up in the eye (ocular hypertension)
By signing up, I agree to GoodRx's Terms and Privacy Policy, and to receive marketing messages from GoodRx.
Berdahl, J. P., et al. (2024). Efficacy and safety of the travoprost intraocular implant in reducing topical IOP-lowering medication burden in patients with open-angle glaucoma or ocular hypertension. Drugs.
Boyd, K. (2023). About corneal transplantation. American Academy of Ophthalmology.
Boyd, K. (2023). What is ocular hypertension? American Academy of Ophthalmology.
Denis, P., et al. (2007). Travoprost in the management of open-angle glaucoma and ocular hypertension. Clinical Ophthalmology.
Glaukos Corporation. (2023). idose TR- travoprost intracameral implant [package insert]. DailyMed.
Glaukos Corporation. (n.d.). About iDose® TR.
Hong, A., et al. (2023). Descemet stripping endothelial keratoplasty. American Academy of Ophthalmology.
Ichhpujani, P., et al. (2023). iDose TR sustained-release travoprost implant for the treatment of glaucoma. U.S. Ophthalmic Review.
MedlinePlus. (2018). Fuchs endothelial dystrophy.
National Eye Institute. (n.d.). Macular edema.
Sarkisian, S. R., et al. (2024). Travoprost intracameral implant for open-angle glaucoma or ocular hypertension: 12-month results of a randomized, double-masked trial. Ophthalmology and Therapy.
Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.